I'm happy to be here on my first earnings call and pleased to be joined this morning by President and CEO Joe Scalzo and Chris Bealer, Chief Financial Officer. A copy of our earnings release and accompanying presentation is available on the investors section of the company's website at thesimplygoodfoodscompany.com. Due to the company's asset light business model, we evaluate our performance on an adjusted basis as it relates to EBITDA and diluted EPS. Our second quarter net sales of $326 million and adjusted EBITDA of $55.5 million were both well below our expectations.
Our fiscal year 2026 guidance now calls for net sales in the range of $1.31 billion-$1.35 billion and adjusted EBITDA of $217 billion-$225 million. I believe Simply Good Foods can return to delivering the durable long-term growth that you would expect from a leading nutrition company. With that perspective, I'll turn the call over to Chris, who will provide more details on this quarter's results and our updated outlook for the year. After Chris is finished, I'll return to discuss how we plan to get our performance back on track.
Quest consumption grew 2.4% as bars were impacted by softer baseline velocities. Salty grew 14% in the quarter, although this represented a deceleration from Q1. Gross margin was 31.6%, a decline of 460 basis points versus prior year, largely reflecting higher input costs and some one-time effects from actions taken to mitigate OWYN product quality issues. Gross margin was 32.8%, a 350 basis point decline versus the same period last year.
| Metric | Period | Current guidance |
|---|---|---|
| Net sales | Full year fiscal 2026 | $1.31 billion to $1.35 billion (down 10% to 7%) (Lowered) |
| Adjusted EBITDA | Full year fiscal 2026 | $217 million to $225 million (down 22% to 19%) (Lowered) |
| GAAP gross margin | Full year fiscal 2026 | Decline of 300 to 350 basis points, with Q4 margin expansion |
| Net sales | Q3 fiscal 2026 | $328 million to $339 million (down 14% to 11%) |
| Adjusted EBITDA | Q3 fiscal 2026 | $46 million to $50 million (down 38% to 32%) |
| Effective tax rate | Full year fiscal 2026 | Roughly 25% |
| Weighted average diluted share count | Full year fiscal 2026 | Approximately 92 million shares |
| One-time fixed-cost initiative cost | Fiscal 2026 | Approximately $15 million including CEO transition costs |
| Metric | YoY | Note |
|---|---|---|
| Net sales | Down 9.4% to $326 million | Weaker consumption across the portfolio, especially Atkins distribution losses and softer Quest and OWYN velocities. |
| Adjusted EBITDA | Down 18.4% to $55.5 million | Lower sales and gross margin compression from input cost inflation. |
| Gross margin | Down 460 bps to 31.6% (350 bps ex one-time items) | Higher input costs, most notably cocoa and whey, tariffs, and one-time OWYN product quality mitigation costs. |
| Atkins consumption | Down 23.4% | Known distribution losses and related trade inventory reductions, roughly in line with expectations. |
| Salty snacks consumption | Up 14% | Continued growth, though a deceleration from Q1. |
| G&A expenses (adjusted) | Down 12% to $29.3 million | Reduction in short-term incentive accrual and increased focus on controlling G&A amid the management transition. |
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Turnaround and structural reset | — | New CEO diagnosing eroded household fundamentals, prioritizing fewer bigger ideas, restored brand investment, and a rebuilt P&L structure | Early stage |
| Input cost inflation | Cocoa expected to ease | Cocoa savings still expected to start in Q4, but whey, whey isolate, and milk isolate at historic highs partially offset cocoa relief | Mixed, with protein costs rising |
| Pricing and promotion strategy | Increased reliance on price promotion | Reducing low-return price promotion and using justified pricing to recover gross margin lost to inflation | Shifting away from promotion |
| Brand portfolio roles | Quest and OWYN expected to bolster results while fixing Atkins | Quest is the primary growth driver, OWYN being reset after execution issues, and Atkins positioned for GLP-1 users after resizing | Broader work needed |
| GLP-1 medications | — | Viewed as a tailwind reinforcing demand for nutrient-dense, high-protein products, with research underway for Atkins positioning | Emerging opportunity |
| Fixed-cost reduction | G&A growing faster than the business | Major initiative to reduce staffing and overhead, with first quarter of savings expected in Q4 | Underway |